Forward

Restructure Information


On April 28, 2026, the U.S. District Court for the District of New Jersey sentenced Purdue Pharma L.P. in connection with its 2020 Plea Agreement with the U.S. Department of Justice. Purdue is operating as usual and without interruption until May 1, 2026, when it will permanently cease operations. On that day, substantially all of Purdue’s assets will be transferred to a newly formed company, Knoa Pharma LLC. Medicines distributed though Purdue will then be distributed by Knoa Pharma.

READ MORE HERE >

With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.

About Us

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapeutics.

Learn More

Pipeline

Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.

Learn More

Collaboration

Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@pharma.com .